These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 27418267)
21. Comparative evaluation of transport mechanisms of trans-1-amino-3-[¹⁸F]fluorocyclobutanecarboxylic acid and L-[methyl-¹¹C]methionine in human glioma cell lines. Ono M; Oka S; Okudaira H; Schuster DM; Goodman MM; Kawai K; Shirakami Y Brain Res; 2013 Oct; 1535():24-37. PubMed ID: 23994214 [TBL] [Abstract][Full Text] [Related]
22. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Pafundi DH; Laack NN; Youland RS; Parney IF; Lowe VJ; Giannini C; Kemp BJ; Grams MP; Morris JM; Hoover JM; Hu LS; Sarkaria JN; Brinkmann DH Neuro Oncol; 2013 Aug; 15(8):1058-67. PubMed ID: 23460322 [TBL] [Abstract][Full Text] [Related]
23. Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, Collet S; Guillamo JS; Berro DH; Chakhoyan A; Constans JM; Lechapt-Zalcman E; Derlon JM; Hatt M; Visvikis D; Guillouet S; Perrio C; Bernaudin M; Valable S J Nucl Med; 2021 Oct; 62(10):1349-1356. PubMed ID: 34016725 [TBL] [Abstract][Full Text] [Related]
24. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma. Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210 [TBL] [Abstract][Full Text] [Related]
34. Comparison of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid (anti-[18F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats. Kanagawa M; Doi Y; Oka S; Kobayashi R; Nakata N; Toyama M; Shirakami Y Nucl Med Biol; 2014 Aug; 41(7):545-51. PubMed ID: 24816330 [TBL] [Abstract][Full Text] [Related]
35. [Sequential analysis of the integrated images of PET, CT and MR in malignant brain tumors before and after radiotherapy]. Suzuki A; Mineura K; Sasajima T; Kowada M; Ogawa T; Hatazawa J; Uemura K No To Shinkei; 1996 May; 48(5):449-57. PubMed ID: 8672304 [TBL] [Abstract][Full Text] [Related]
37. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas]. Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188 [TBL] [Abstract][Full Text] [Related]
38. Fasting Enhances the Contrast of Bone Metastatic Lesions in Oka S; Kanagawa M; Doi Y; Schuster DM; Goodman MM; Yoshimura H Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28468238 [No Abstract] [Full Text] [Related]
39. Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. Amzat R; Taleghani P; Miller DL; Beitler JJ; Bellamy LM; Nye JA; Yu W; Savir-Baruch B; Osunkoya AO; Chen Z; Auffermann WF; Goodman MM; Schuster DM Mol Imaging Biol; 2013 Oct; 15(5):633-43. PubMed ID: 23595643 [TBL] [Abstract][Full Text] [Related]